Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Completed · Phase 3

Conditions studied: Cystic Fibrosis

In brief

This study evaluated the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).

Key facts

Study ID
NCT04058366
Run by
Vertex Pharmaceuticals Incorporated
People needed
251
Starts
2019-12-05
Expected to finish
2022-12-16
Last updated by the study team
2024-01-16

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.